China Resources Pharmaceutical : ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF JIANGZHONG PHARMACEUTICAL FOR THE SIX MONTHS ENDED 30 JUNE 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF

JIANGZHONG PHARMACEUTICAL FOR

THE SIX MONTHS ENDED 30 JUNE 2020

On 25 August 2020, Jiangzhong Pharmaceutical released its interim report for the six months ended 30 June 2020.

Jiangzhong Pharmaceutical Co . , Ltd .（ 江 中 藥 業 股 份 有 限 公 司）("Jiangzhong Pharmaceutical") is a company incorporated in the People's Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is indirectly owned as to approximately 43.03% by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and is a subsidiary of the Company.

1

On 25 August 2020, Jiangzhong Pharmaceutical released its interim report for the six months ended 30 June 2020 (the "Jiangzhong Pharmaceutical Unaudited Financials"). Set out below is the key financial information of the Jiangzhong Pharmaceutical Unaudited Financials:

	As of	As of
	30 June	31 December	Increase/
	2020	2019	decrease
	(RMB)	(RMB)	(%)
	(unaudited)	(audited)
Total assets	4,690,504,075.67	4,759,193,757.25	-1.44%
Net assets attributable to shareholders of
the listed company	3,673,131,070.18	3,560,628,579.69	3.16%
	For the six months ended 30 June	Increase/
	2020	2019	decrease
	(RMB)	(RMB)	(%)
	(unaudited)	(unaudited)
Revenue	1,158,461,610.44	1,140,918,626.22	1.54%
Net profit attributable to the shareholders
of the listed company	270,002,490.49	252,001,735.13	7.14%
Net profit attributable to the shareholders
of the listed
company (after extraordinary
gains or losses)	266,370,628.12	234,878,138.20	13.41%
Net cash flow from operating activities	690,545,105.25	473,874,065.39	45.72%
Basic earnings per share (RMB/share)	0.43	0.40	7.50%
Diluted earnings per share (RMB/share)	0.43	0.40	7.50%
			-0.14 percentage
Weighted average return on net asset (%)	7.31%	7.45%	point

2

Note: In June 2020, Jiangzhong Pharmaceutical fully implemented its profit distribution plan for the year 2019, the share capital of Jiangzhong Pharmaceutical increased from 525,000,000 shares to 630,000,000 shares. Pursuant to the "Information Disclosure Compiling Rule No. 9 of Public Offering Company about the Calculation and Disclosure of Net Asset Income Rate and Earnings Per Share (2010 Amendments)" promulgated by the CSRC, during the reporting period, basic earnings per share, diluted earnings per share, and basic earnings per share after deducting non-recurring gains and losses attributable to the shareholders of the listed companies for the respective comparative periods shall be recalculated according to the adjusted number of shares.

The Jiangzhong Pharmaceutical Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should

exercise caution when dealing in securities of the Company and should not rely solely on such information.

For further details of the Jiangzhong Pharmaceutical Unaudited Financials, please refer to the interim report for the six months ended 30 June 2020 published by Jiangzhong Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors

China Resources Pharmaceutical Group Limited

WANG Chuncheng

Chairman

Shenzhen, 26 August 2020

As of the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.

3